Shots:
- The EU granted marketing authorization to Beyonttra (acoramidis) to treat wild-type or variant ATTR-CM in adult pts.; launch expected in 1H’25
- The approval was supported by the results of P-III (ATTRibute-CM) study of Beyonttra (BID, oral) vs PBO (n=632) in ATTR-CM pts.. It achieved its 1EP, showing a 42% reduced composite ACM & recurrent CVH events & 50% reduced cumulative frequency of CVH events at 30mos.
- As per the March’24 agreement, BridgeBio will receive $75M milestone payment from Bayer upon EU approval, along with tiered royalties starting in the low thirties percent on acoramidis sales in the EU; approval is under review by the PMDA and ANVISA
Ref: BridgeBio | Image: BridgeBio
Related News:- BridgeBio & Bayer Report the CHMP’s Positive Opinion of Beyonttra (Acoramidis) to Treat Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
